Extended energy without the caffeine crash
zümXR®'s controlled-release mechanism smooths caffeine's pharmacokinetic profile — reducing the sharp peak that drives jitteriness and anxiety in sensitive users and extending the effective duration from 3–4 hours (standard caffeine) to 6–8 hours. This smoothed, extended profile is ideal for all-day energy products, endurance sports, and consumers who need sustained cognitive performance without repeated dosing.
Reduced peak side effects
By distributing caffeine release over a longer time window, zümXR® reduces the peak plasma caffeine concentration responsible for jitteriness, heart palpitations, and anxiety in caffeine-sensitive individuals. The same total caffeine dose produces fewer side effects with targeted release vs. immediate release — enabling users to benefit from caffeine's cognitive and performance effects at doses that would otherwise cause discomfort.
Sustained athletic performance and endurance support
For endurance athletes in events lasting 3+ hours, zümXR®'s extended caffeine release maintains the ergogenic caffeine concentration throughout a longer performance window — reducing the need for mid-race caffeine re-dosing (which can be impractical) while avoiding early-race caffeine peaks that may cause GI distress in some athletes.
Microencapsulation controlled-release caffeine pharmacokinetics
zümXR® uses a proprietary coating or microencapsulation technology to delay and extend caffeine dissolution in the GI tract. The release mechanism provides an initial immediate-release fraction (for onset) combined with a sustained-release fraction (for duration) — producing a biphasic release profile that extends effective plasma caffeine levels while reducing the peak concentration. The underlying pharmacology of caffeine (adenosine receptor antagonism, PDE inhibition) is identical to standard caffeine once released; zümXR® only modifies the delivery kinetics.
Clinical pharmacokinetic study comparing zümXR® extended-release caffeine vs. immediate-release caffeine for plasma concentration time curve, peak levels, and duration of action.
Healthy adults. Pharmacokinetic crossover design.
zümXR® produced extended caffeine plasma levels vs. immediate release, with reduced peak concentration and prolonged time above effective threshold. Energy and cognitive benefits sustained longer. Side effects (jitteriness, heart rate elevation) reduced vs. equivalent immediate-release dose. Confirms zümXR® delivery technology for extended-duration caffeine applications.